Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hellmann

Showing results (61-70 of 235) with videos related to

Pageof 24
Sort By:
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|June 15, 2016
Motor unit activity within the depth of the masseter characterized by an adapted scanning EMG techniqueJ P van Dijk, U Eiglsperger, D Hellmann, et al.
Cancer|March 18, 2015
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomasHelena A Yu, Camelia S Sima, Matthew D Hellmann, et al.
Clinical Chemistry and Laboratory Medicine|March 21, 2001
Alkaline phosphatase activity: new assay for the Reflotron system. Results of the evaluation in eight clinical laboratoriesG Schumann, H C Dominick, D Hellmann, et al.
Journal for Immunotherapy of Cancer|November 22, 2018
Acquired resistance to immunotherapy in MMR-D pancreatic cancerZishuo Ian Hu, Matthew D Hellmann, Jedd D Wolchok, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomasJuliana B Schilsky, Ai Ni, Linda Ahn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 2, 2019
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancerNarek Shaverdian, Michael D Offin, Andreas Rimner, et al.
Immunity|January 5, 2022
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor typesAparna Chhibber, Lingkang Huang, Hong Zhang, et al.
Cancer Immunology Research|December 14, 2016
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 BlockadeTavi Nathanson, Arun Ahuja, Alexander Rubinsteyn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 4, 2015
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung AdenocarcinomasJuliana Eng, Kaitlin M Woo, Camelia S Sima, et al.
Lung Cancer (Amsterdam, Netherlands)|September 18, 2021
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancerSandra Huicochea Castellanos, Andrew Pagano, Andrew J Plodkowski, et al.
Pageof 24

Showing results (61-70 of 235) with videos related to

Sort By:
Pageof 24
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|June 15, 2016
Motor unit activity within the depth of the masseter characterized by an adapted scanning EMG techniqueJ P van Dijk, U Eiglsperger, D Hellmann, et al.
Cancer|March 18, 2015
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomasHelena A Yu, Camelia S Sima, Matthew D Hellmann, et al.
Clinical Chemistry and Laboratory Medicine|March 21, 2001
Alkaline phosphatase activity: new assay for the Reflotron system. Results of the evaluation in eight clinical laboratoriesG Schumann, H C Dominick, D Hellmann, et al.
Journal for Immunotherapy of Cancer|November 22, 2018
Acquired resistance to immunotherapy in MMR-D pancreatic cancerZishuo Ian Hu, Matthew D Hellmann, Jedd D Wolchok, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomasJuliana B Schilsky, Ai Ni, Linda Ahn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 2, 2019
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancerNarek Shaverdian, Michael D Offin, Andreas Rimner, et al.
Immunity|January 5, 2022
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor typesAparna Chhibber, Lingkang Huang, Hong Zhang, et al.
Cancer Immunology Research|December 14, 2016
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 BlockadeTavi Nathanson, Arun Ahuja, Alexander Rubinsteyn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 4, 2015
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung AdenocarcinomasJuliana Eng, Kaitlin M Woo, Camelia S Sima, et al.
Lung Cancer (Amsterdam, Netherlands)|September 18, 2021
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancerSandra Huicochea Castellanos, Andrew Pagano, Andrew J Plodkowski, et al.
Pageof 24